ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PAVMU Pavmed (MM)

14.53
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pavmed (MM) NASDAQ:PAVMU NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.53 10.44 30.00 0 01:00:00

PAVmed Announces Initiation of Research Coverage by The Benchmark Company

26/07/2016 8:10pm

Business Wire


Pavmed (MM) (NASDAQ:PAVMU)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Pavmed (MM) Charts.

PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that Jan David Wald, Ph.D., Senior Research Analyst at The Benchmark Company, has initiated research coverage on PAVmed.

For more information on this report please contact John Borer at investmentbanking@benchmarkcompany.com.

About PAVmed

PAVmed Inc. (Nasdaq: PAVMU) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com.

About The Benchmark Company

Headquartered in New York City, The Benchmark Company, LLC is an institutional investment banking firm with a strong sales/trading presence, in addition to its research and investment banking arms.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of the Company's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

For PAVmed Inc.InvestorsMatthew Ventimiglia, 212-599-1265mventimiglia@lazarpartners.comorMediaGlenn Silver, 646-871-8495gsilver@lazarpartners.com

1 Year Pavmed (MM) Chart

1 Year Pavmed (MM) Chart

1 Month Pavmed (MM) Chart

1 Month Pavmed (MM) Chart